HilleVax Strategic Review: Cash Position, Workforce Reductions, and Potential Strategic Alternatives
HilleVax trades at a 46% discount to net cash, with potential upside from strategic review outcomes like liquidation or sale.
262 Views
Analyzing Active Quick Pitches: Takeovers, Tender Offers, Strategic Reviews and More
Theratechnologies (THTX) received takeover offers from Future Pak, with a $3.51/share cash offer plus a CVR worth $0.99/share.
409 Views
Exploring Strategic Reviews: Key Opportunities in Biopharma and Food Sectors
Lifeway Foods (LWAY) faces a pending takeover by Danone, with a potential board overhaul and strategic acquisition synergies.
307 Views
Current Investment Opportunities: Mergers, Liquidations, Strategic Reviews and More
NIOX Group received a non-binding takeover proposal from Keensight Capital at 81p/share, with ongoing negotiations and a deadline of April 17.
222 Views
Strategic Reviews, Liquidations, and Buybacks: Key Financial Developments in Biopharma, Real Estate
Kronos Bio (KRON) undergoes strategic review with 83% workforce reduction and CEO resignation, trading below net cash value.
40 Views